Canada Outpaces OECD Countries in New Medicine Launches Despite Rising Treatment Costs
Key Insights
Canada launched more new medicines than the median for OECD countries in 2022-2023, according to the PMPRB's 9th annual Meds Entry Watch report.
Most new medicines entering the Canadian market carry high treatment costs exceeding $10,000 per year or $5,000 per 28-day cycle for oncology treatments (search).
Specialty medicines including biologics, orphan drugs (search), and cancer (search) treatments represent a growing share of the new drug landscape in Canada.
The Patented Medicine Prices Review Board (search) (PMPRB) released findings showing Canada continues to exceed the median number of new medicine launches among Organisation for Economic Co-operation and Development (OECD) countries, despite mounting concerns over escalating treatment costs that now routinely surpass $10,000 annually.
The 9th edition of the annual Meds Entry Watch report, published June 17, 2025, reveals that most new medicines entering the Canadian market carry substantial price tags, with treatments costing over $10,000 per year or $5,000 per 28-day cycle for oncology therapies becoming the norm rather than the exception.
Specialty Medicines Drive Market Growth
The analysis demonstrates that specialty medicines, including biologic therapies (search), orphan drugs (search), and cancer (search) treatments, continue to constitute an expanding portion of Canada's new drug landscape. This trend reflects the pharmaceutical industry's increasing focus on complex, targeted therapies for rare diseases (search) and specialized medical conditions.
The PMPRB's comprehensive review examined medicines approved by three major regulatory bodies: the US Food and Drug Administration (search) (FDA), the European Medicines Agency (search) (EMA), and Health Canada. The report specifically analyzed trends in the market for new medicines approved since 2018.
2022-2023 Approval Data
The report highlighted 48 medicines that received first-time market approval in 2022, while providing preliminary analysis of 63 medicines approved in 2023. This data underscores the continued robust pipeline of new therapeutic options reaching Canadian patients, even as cost considerations become increasingly prominent in healthcare decision-making.
Market Dynamics and Decision-Making Impact
According to the PMPRB, the publication serves to inform decision makers, researchers, and patients about the evolving market dynamics of emerging therapies in both Canadian and international pharmaceutical markets. The consistent pattern of Canada outperforming OECD medians in new medicine availability suggests the country maintains competitive access to innovative treatments despite pricing pressures.
The findings reflect broader global trends in pharmaceutical development, where breakthrough therapies for previously untreatable conditions command premium pricing, while healthcare systems grapple with balancing patient access against budget sustainability.